Chemomab Therapeutics (CMMB)
(Real Time Quote from BATS)
$1.13 USD
+0.01 (0.89%)
Updated Jul 22, 2024 03:02 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CMMB 1.13 +0.01(0.89%)
Will CMMB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMMB
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Other News for CMMB
Chemomab Therapeutics (CMMB) Gets a Buy from Roth MKM
Maxim Group Sticks to Its Buy Rating for Chemomab Therapeutics (CMMB)
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab: Publications 'reinforce' potential of I CCL24 antibody for PSC
Chemomab Therapeutics management to meet virtually with Roth MKM